In addition, SELLAS announced today that ZELTHERVA has been formally accepted by the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research as the proprietary name for SELLAS ‘s WT1 vaccine is a late clinical-stage cancer immunotherapy being developed to target hematologic cancers and solid tumors, including AML, MPM, multiple myeloma, ovarian cancer, and multiple other cancers. Based on the results of its mid-stage clinical program, SELLAS expects to begin a pivotal Phase 3 trial of its WT1 vaccine in AML patients and a pivotal Phase 2b/3 trial of its WT1 vaccine in patients with MPM later this year.
